Logo

Chimerix Signs an Exclusive Worldwide License Agreement with Cantex for CX-01 to Treat Acute Myeloid Leukemia

Share this

Chimerix Signs an Exclusive Worldwide License Agreement with Cantex for CX-01 to Treat Acute Myeloid Leukemia

Shots:

  • Cantex to receive $30M up front- $587.5M regulatory and commercial milestones and royalties starting at 10%. Chimerix to get exclusive WW rights to develop and commercialize Cantex’s CX-01 and has also issued $10M shares in its common stock to Cantex
  • The focus of the agreement is to accelerate and advance the development of CX-01 with the initiation of P-III trial for treating 1L AML patients in H2’20
  • CX-01 is a chemical candidate derived from unfractionated heparin with very low anticoagulant activity targeting protein pathways for AML and has also received the US FDA’s FT designation. CX-01 was recently evaluated in P-II trial with newly diagnosed AML demonstrated well tolerated results

Click here to­ read full press release/ article | Ref: Chimerix | Image: Behnace



Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions